for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Bavarian Nordic: Additional Positive Data From Phase 2 Study

March 6 (Reuters) - BAVARIAN NORDIC A/S:

* REG-BAVARIAN NORDIC ANNOUNCES ADDITIONAL POSITIVE DATA FROM A PHASE 2 STUDY OF ITS UNIVERSAL RSV VACCINE

* SAYS TODAY ANNOUNCED ADDITIONAL POSITIVE DATA FROM ITS 421 PATIENT

* PRESENCE OF ANTIBODIES IN NASAL MUCOSA SUGGEST VACCINE-INDUCED IMMUNE PROTECTION AT SOURCE OF INFECTION

* IGA ANTIBODIES AGAINST RSV OBSERVED IN BOTH SERUM AND MUCOSA OF VACCINATED INDIVIDUALS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up